Suppr超能文献

依诺肝素在高通量血液透析、延长血液透析及血液透析滤过过程中预防凝血的疗效。

Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration.

作者信息

Santos Alba, Macías Nicolás, Vega Almudena, Abad Soraya, Linares Tania, Aragoncillo Inés, Cruzado Leonidas, Pascual Cristina, Goicoechea Marian, López-Gómez Juan Manuel

机构信息

Nephrology Department, Hospital Universitario del Vinalopó, Elche, Spain.

Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

出版信息

Clin Kidney J. 2020 Jun 22;14(4):1120-1125. doi: 10.1093/ckj/sfaa057. eCollection 2021 Apr.

Abstract

BACKGROUND

Low-molecular-weight heparins (LMWHs) are easily dialysable with high-flow membranes; however, it is not clear whether the LMWH dose should be adjusted according to the membrane type and dialysis technique. This study aimed to evaluate the influence of the dialyser on anticoagulation of the extracorporeal dialysis circuit.

METHODS

Thirteen patients received the same dose of LMWH through the arterial port via three dialysis techniques: high-flux haemodialysis (HF-HD), online haemodiafiltration (HDF) and expanded haemodialysis (HDx). All dialysis was performed under similar conditions: duration, 4 h; blood flow, 400 mL/min; and dialysate flow, 500 mL/min. Antifactor Xa (aXa) activity and activated partial thromboplastin time (APTT) were measured before and after the dialysis. Clotting time of the vascular access site after haemodialysis, visual clotting score of the dialyser and any complications with the extracorporeal circuit or bleeding were registered.

RESULTS

Post-dialysis aXa activity in HF-HD (0.26 ± 0.02 U/mL) was significantly different from that in HDF (0.21 ± 0.02 U/mL, P = 0.024), and there was a trend in HDx (0.22 ± 0.01 U/mL, P = 0.05). APTT post-dialysis in HF-HD (30.5 ± 0.7 s) was significantly different from that in HDx (28.2 ± 0.64 s, P = 0.009) and HDF (28.8 ± 0.73 s, P = 0.009).

CONCLUSIONS

AXa activity in HDF was significantly lower than that in HF-HD, possibly because of more losses of LMWH through the dialyser. Given the higher anticoagulant loss in HDF and probably in HDx than in HF-HD, the enoxaparin dose administered may be adjusted according to the dialysis technique.

摘要

背景

低分子量肝素(LMWHs)可通过高流量膜轻松透析;然而,尚不清楚LMWH剂量是否应根据膜类型和透析技术进行调整。本研究旨在评估透析器对体外透析回路抗凝的影响。

方法

13名患者通过三种透析技术经动脉端口接受相同剂量的LMWH:高通量血液透析(HF-HD)、在线血液透析滤过(HDF)和扩展血液透析(HDx)。所有透析均在相似条件下进行:持续时间4小时;血流量400毫升/分钟;透析液流量500毫升/分钟。在透析前后测量抗Xa因子(aXa)活性和活化部分凝血活酶时间(APTT)。记录血液透析后血管通路部位的凝血时间、透析器的视觉凝血评分以及体外回路的任何并发症或出血情况。

结果

HF-HD组透析后aXa活性(0.26±0.02 U/mL)与HDF组(0.21±0.02 U/mL,P = 0.024)有显著差异,HDx组有此趋势(0.22±0.01 U/mL,P = 0.05)。HF-HD组透析后APTT(30.5±0.7秒)与HDx组(28.2±0.64秒,P = 0.009)和HDF组(28.8±0.73秒,P = 0.009)有显著差异。

结论

HDF组的aXa活性显著低于HF-HD组,可能是因为LMWH通过透析器的损失更多。鉴于HDF组以及可能HDx组的抗凝剂损失高于HF-HD组,可根据透析技术调整依诺肝素的给药剂量。

相似文献

1
Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration.
Clin Kidney J. 2020 Jun 22;14(4):1120-1125. doi: 10.1093/ckj/sfaa057. eCollection 2021 Apr.
2
8
Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
Nephrol Dial Transplant. 2003 Oct;18(10):2097-104. doi: 10.1093/ndt/gfg272.

引用本文的文献

1
Anticoagulation in Chronic Kidney Disease.
Drugs. 2024 Oct;84(10):1199-1218. doi: 10.1007/s40265-024-02077-6. Epub 2024 Aug 9.
2
Update on the Pharmacological Actions of Enoxaparin in Nonsurgical Patients.
Medicina (Kaunas). 2024 Jan 15;60(1):156. doi: 10.3390/medicina60010156.
3
Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels.
Clin Pharmacokinet. 2022 Nov;61(11):1559-1569. doi: 10.1007/s40262-022-01162-x. Epub 2022 Aug 30.
4
Clinical Outcomes With Medium Cut-Off Versus High-Flux Hemodialysis Membranes: A Systematic Review and Meta-Analysis.
Can J Kidney Health Dis. 2022 Jan 21;9:20543581211067087. doi: 10.1177/20543581211067087. eCollection 2022.
5
Effects of Medium Cut-Off Versus High-Flux Hemodialysis Membranes on Biomarkers: A Systematic Review and Meta-Analysis.
Can J Kidney Health Dis. 2022 Jan 18;9:20543581211067090. doi: 10.1177/20543581211067090. eCollection 2022.

本文引用的文献

1
Renal Association Clinical Practice Guideline on Haemodialysis.
BMC Nephrol. 2019 Oct 17;20(1):379. doi: 10.1186/s12882-019-1527-3.
2
Middle molecule elimination in expanded haemodialysis: only convective transport?
Clin Kidney J. 2018 Dec 15;12(3):447-455. doi: 10.1093/ckj/sfy097. eCollection 2019 Jun.
4
Is Expanded Hemodialysis an Option to Online Hemodiafiltration for Small- and Middle-Sized Molecules Clearance?
Blood Purif. 2019;47(1-3):126-131. doi: 10.1159/000493910. Epub 2018 Oct 12.
5
Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms.
Clin Appl Thromb Hemost. 2018 Mar;24(2):310-316. doi: 10.1177/1076029617741363. Epub 2017 Dec 6.
6
Expanded Hemodialysis Therapy: Prescription and Delivery.
Contrib Nephrol. 2017;191:153-157. doi: 10.1159/000479263. Epub 2017 Sep 14.
9
MCO Membranes: Enhanced Selectivity in High-Flux Class.
Sci Rep. 2015 Dec 16;5:18448. doi: 10.1038/srep18448.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验